Sistemski lupus eritematosus pasa

master's thesis

• Title (english): Systemic Lupus Erythematosus
• Author: Lina Sokolić
• Mentor: Mirna Brkljačić (mentor)
• Mentor: Ivana Kiš (mentor)
• Committee member: Gabrijela Jurkić Krsteska (predsjednik povjerenstva)
• Committee member: Mirna Brkljačić (član povjerenstva)
• Committee member: Ivana Kiš (član povjerenstva)
• Granter: University of Zagreb; Faculty of Veterinary Medicine; Zagreb
• Defense date and country: 2025-01-16, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Veterinary Medicine; Veterinary Clinical Sciences

Abstract

Sistemski lupus eritematosus (SLE) je multisistemska, imunosno posredovana bolest
kod koje organizam stvara protutijela protiv antigena vlastitih tkiva i organa, što rezultira
stvaranjem velikog broja cirkulirajućih imunih kompleksa. Imuni kompleksi se talože na
različitim mjestima u organizmu, što dovodi do upale i nastanka oštećenja tkiva reakcijom
preosjetljivosti tipa III. Uzrok bolesti nije otkriven, no utvrđeno je kako u patogenezi sudjeluju
genetski i okolišni čimbenici te izloženost određenim infektivnim uzročnicima i lijekovima.
Klinička slika SLE-a je varijabilna i može zahvatiti različite organske sustave zbog čega je
dijagnostika kompleksna i izazovna, a temelji se uglavnom, na kombinacijama prilagođenih
kriterija preuzetih iz humane medicine. Najčešći klinički znakovi su vrućica, hromost i/ili
oticanje zglobova, dermatološki simptomi te znakovi zatajenja bubrega poput gubitka tjelesne
mase, povraćanja te sindroma poliurije i polidipsije. Bolest je neizlječiva, a liječenje zahtjevno
te obuhvaća često dugotrajnu ili doživotnu imunosupresivnu terapiju kortikosteroidima ili
kombiniranim imunosupresivnim protokolima koji uključuju više lijekova. Redovne kontrole
vrlo su bitne za pozitivan odgovor na terapiju zbog učestalih recidiva i nuspojava od strane
imunosupresivne terapije. Prognoza SLE-a je rezervirana zbog nepredvidivog tijeka bolesti i
individualnog odgovora na terapiju.

Abstract (english)

Systemic lupus erythematosus (SLE) is a multisystemic, immune-mediated disease in
which the body produces antibodies against antigens of its own tissues and organs, resulting in
the formation of a large number of circulating immune complexes. Immune complexes deposit
in various locations in the body, leading to inflammation and tissue damage through a type III
hypersensitivity reaction. The cause of the disease has not been discovered, but it has been
established that genetic and environmental factors, as well as exposure to certain infectious
agents and drugs, are involved in its pathogenesis. The clinical presentation of SLE is variable
and can affect different organ systems, making diagnosis complex and challenging, relying
primarily on combinations of adapted criteria borrowed from human medicine. The most
common clinical signs are fever, lameness and/or joint swelling, dermatological symptoms,
and signs of kidney failure such as weight loss, vomiting, and syndromes of polyuria and
polydipsia. The disease is incurable, and treatment is demanding, often requiring long-term or
lifelong immunosuppressive therapy with corticosteroids or combined immunosuppressive
protocols involving multiple drugs. Regular check-ups are crucial for a positive response to
therapy due to frequent relapses and side effects from immunosuppressive treatment. The
prognosis for SLE is guarded due to the unpredictable course of the disease and individual
response to therapy.

• Keywords: sistemski lupus eritematosus; imunosno posredovana bolest; pas; dijagnostika
• Keywords (english): systemic lupus erythematosus; immune-mediated disease; dog; diagnostics
• Language: croatian
• URN:NBN: urn:nbn:hr:178:283272
• Study programme: Title: Veterinary Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica veterinarske medicine (doktor/doktorica veterinarske medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2025-01-22 08:17:17